



WELCOME TO

ESPN/ERKNet

Educational Webinars on Pediatric Nephrology &
Rare Kidney Diseases





Date: 11 February 2020

Topic: Genetics - basic concepts and testing


Speaker: Beata Lipska-Zietkiewicz

Not all congenital diseases are hereditary but all hereditary diseases are congenital, even if the symptoms occur later in life.





*a pocket dictionary
to the
GENETIC LANGUAGE*



Mutation

- Variant classification and assessment
- Homozygosity, heterozygosity, compound heterozygosity

Penetrance

Expresivity

Genetic heterogeneity

- Locus heterogeneity
- Allele heterogeneity


Mosaicism

Mutation

- **Variant** classification and assessment


ACMG criteria 2015

- ✓ Discussion in the multidisciplinary environment
- ✓ Check the databases: ClinVar, GnomAD, LOVD, HGMD,...
- ✓ Review journal papers, GeneReviews
- ✓ Consult experts e.g. CPMS vis ERKnet




Mutation

- Variant classification and assessment



Mutation

- Variant classification and assessment



id.BRCA
Breast Cancer

Probability of pathogenicity

4

Example Mutation


Variants that are previously unreported but are expected to be deleterious

Impact on patient management

Treat as Class 5 patients, despite small risk of over-treatment. May warrant additional follow up studies to assess significance and potentially reclassify, e.g. segregation studies.

Mutation

- Variant classification and assessment



id.BRCA
Breast Cancer

Probability of pathogenicity


3

Example Mutation


Clinical significance unknown

Impact on patient management


Additional follow up studies necessary to assess significance and potentially reclassify, e.g. segregation studies, in-vitro/in-vivo assays...



HOMOZYGOTE



COMPOUND HETEROZYGOTE




HETEROZYGOTE

Penetrance


Expressivity

PENETRANCE


frequency of expression of a particular gene expressed in percentages or numerical values, indicating the proportion of people with the mutant allele, in which a particular trait (e.g. symptoms of the disease) exhibit a phenotype.




Variable expressivity



Variable penetrance



Variable penetrance and expressivity



EXPRESIVITY


Determines to what extent (and in which clinical form) the particular allele reveals in phenotype of the individual.

Genetic heterogeneity


- Locus heterogeneity
- Allele heterogeneity

LOCUS HETEROGENITY

producing similar phenotypes by mutations located in different *loci*.




The *PKD1* gene is located on the short (p) arm of [chromosome 16](#) at position 13.3.





The *PKD2* gene is located on the long (q) arm of [chromosome 4](#) at position 22.1.

ALLELE HETEROGENITY

producing different phenotypes by various mutation affecting the same gene (*locus*).




Mosaicism




Mosaicism - the presence in a single person two or more cell lines, which were created from one zygote


Mosaicism




Constitutional
mosaicism



Germline
mosaicism




late somatic event





early somatic event


Mosaicism - the presence in a single person two or more cell lines, which were created from one zygote




Pedigree – the GENETIC alphabet




What is the most likely mode of inheritance?






HOMOZYGOTE

NM_014669.4:c.[1772G>T];[1772G>T]




COMPOUND HETEROZYGOTE

NM_000092.4:c.509G>A(;)4063G>A
NM_000092.4:c.[509G>A];[4063G>A]






HETEROZYGOTE

NM_000495.5:c.[512G>A];[=]




HOMOZYGOTE




HETEROZYGOTE


HOMOZYGOTE




c.[1772T>C];[1772T>C]



HETEROZYGOTE



c.[1772T>C];[=]




Approach to the patient:

	Clinics	vs.	Genetics
DISEASE STATE:	symptomatic cancer patient		at-risk for mutation
CAUSATIVE AGENT	somatic mutation		germline mutation
LOCUS:	organ		pleiotropic
DIAGNOSIS:	tissue pathology		DNA test
INTERVENTION:	medication(s) renal replacement therapy		predictive risk counselling
FAMILY:	patient support		shared risk status

Adopted after: McKellin W „Knowledge translation in cancer : the implications of genetics for cross-cultural cancer care”
Hereditary Cancer Program BCCA www.bccancer.bc.ca/NR/rdonlyres/E46D73B9-B315-490D-81CF-48F51DD19ABE/6203/BillMcKellinKeynote.ppt

GENETIC TESTING IS A MULTI-STEP PROCESS





A normal result does not rule out the diagnosis of a genetic disorder since some DNA abnormalities may be undetectable by the applied technology.

Test results should always be interpreted in the context of clinical findings, family history, and other relevant data.

Next Webinars



ERKNet Advanced Webinars on Rare Kidney Disorders

Date: **25 February 2020**

Speaker: **John Sayer**

Topic: **Joubert Syndrome: molecular genetics and therapy**



IPNA Clinical Practice Webinars

Date: **03 March 2020**

Speaker: **Dieter Haffner**

Topic: **Clinical practice recommendations for growth hormone treatment in children with chronic kidney disease.**




ESPN/ERKNet Educational Webinars on Pediatric Nephrology & Rare Kidney Diseases

Date: **10 March 2020**

Speaker: **Carl Bates**

Topic: **Anomalies of Kidney and Urinary Tract**

Subscribe the ERKNet and IPNA Newsletter and don't miss Webinars!



ERKNet

The European
Rare Kidney Disease
Reference Network



IPNA

International Pediatric Nephrology Association
GREAT CARE FOR LITTLE KIDNEYS. EVERYWHERE